[Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance].
BACKGROUND
This study aimed at using matrix-assisted laser desorption ionization - time of flight mass spectrometer (matrix-assisted laser desorption ionization time-of-flight mass spectrometry, MALDI-TOF-MS) screening the difference serum peptides during epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment and exploring their significance of advanced NSCLC patients.


METHODS
Collect 102 serum samples from 34 advanced NSCLC patients, which are before TKI treatment, best effect of treatment and after progession. Peptides were extracted from the samples and then detected by MALDI-TOF-MS system to get the mass spectra. The mass spectra data was analyzed by the ClinproToolTM software to identify the different serum peptides, and then analyzed the clinical significance of peptides.


RESULTS
Among the 34 patients who received TKI treatment, there were none evaluated as complete response (CR), 11 patients evaluated as PR and 23 patients evaluated as stable disease (SD), with the PFS was 8.0 months (95%CI: 6.6-11.2); overall survival (OS) was 11.4 months (95%CI: 10.6-16.5). After detected the serum from three different points of time, the result showed that they were totally different; 87 different peptide peaks were identified after analysis self-paired serum between the time of best effect and baseline, which included one statistically different [P<0.001, area under curve (AUC)≥0.9] peptide; 96 different peptide peaks were identified after analysis serum between the time of progression and baseline, which included 3 statistically different (P<0.001, AUC≥0.9) peptides; 115 different peptide peaks were identified after analysis serum between the time of progression and best effect, which included 4 statistically different (P<0.001, AUC≥0.9) peptides.


CONCLUSIONS
Theserum peptides of NSCLC patients in the process of TKI treatment are dynamic and the different peptides may be associated with treatment effect and disease progression. However, the features and clinical significance of different peptides need to be validated in the future. .
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Zihe
Z
Wang
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Chuanhao
C
Tang
Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Yi
Y
Liu
National Center of Biomedical Analysis, Beijing 100850, China.
Bin
B
Xu
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Haifeng
H
Qin
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Yangyang
Y
Lei
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Hongjun
H
Gao
National Center of Biomedical Analysis, Beijing 100850, China.
Kun
K
He
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Xiaoqing
X
Liu
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*
D010455:Peptides; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
J Clin Invest. 2006 Jan;116(1):271-84
16395409
J Clin Oncol. 2009 Jun 1;27(16):2653-9
19414683
Clin Cancer Res. 2009 Mar 15;15(6):2076-84
19276259
Nat Biotechnol. 2005 Mar;23(3):291-2
15765078
PLoS One. 2015 Jun 05;10(6):e0128970
26047516
Zhongguo Fei Ai Za Zhi. 2009 Jul 20;12(7):765-9
20719152
Eur Urol. 2009 Dec;56(6):989-96
19282097
Onco Targets Ther. 2013 Oct 21;6:1481-91
24204163
Anal Chem. 2004 Mar 15;76(6):1560-70
15018552
Cancer Sci. 2013 Oct;104(10):1346-52
23863134
Front Biosci (Landmark Ed). 2009 Jan 01;14:3712-23
19273304
Laryngoscope. 2008 Jan;118(1):61-8
18043497
Lancet Oncol. 2012 May;13(5):528-38
22452896
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46
17551144
Cancer Invest. 2012 Jun;30(5):433-46
22571344
Lancet Oncol. 2012 Mar;13(3):239-46
22285168